BACKGROUND: The objective of the current study was to determine whether therapy for childhood acute lymphoblastic leukemia (ALL) results in long-lasting neurologic signs or electrophysiologic injuries within the motor tracts. METHODS: Twenty-seven children who were treated for ALL were studied clinically 5 years after the cessation of therapy by means of motor-evoked potentials (MEPs) elicited by magnetic stimulation transcranially and peripherally. An equal number of healthy children matched with regard to age, gender, and height served as the control group. RESULTS: The MEP latencies to the hands and legs elicited by stimulation at the cortex were prolonged significantly in the children treated for ALL compared with the control group, with the differences being 2.2 milliseconds [ms] (P < 0.001) from the cortex to the thenar on the right side and 2.0 ms (P < 0.001) on the left, and 1.4 ms (P = 0.004) from the cortex to the leg on the right side and 1.3 ms (P = 0.004) on the left. Correspondingly, the MEP latency from the fifth lumbar vertebrae (LV) level to the leg also was prolonged, by 1.0 ms (P = 0.005) on the right side and 0.8 ms (P = 0.005) on the left side. The calculated latency between the cortex and the LV level was not found to be significantly longer in those patients treated for ALL compared with the healthy controls. Neurologic signs, in the form of depressed deep tendon reflexes, were observed in 8% of the patients, whereas approximately 33% of the patients were found to have fine or gross motor difficulties and dysdiadochokinesia. CONCLUSIONS: Neurologic signs still persisted 5 years after therapy for ALL. Approximately 33% of the patients had fine or gross motor difficulties and dysdiadochokinesia, and demyelinative injuries to the peripheral nerve tracts were found proximally but not within the central nervous system. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10503
BACKGROUND: The objective of the current study was to determine whether therapy for childhood acute lymphoblastic leukemia (ALL) results in long-lasting neurologic signs or electrophysiologic injuries within the motor tracts. METHODS: Twenty-seven children who were treated for ALL were studied clinically 5 years after the cessation of therapy by means of motor-evoked potentials (MEPs) elicited by magnetic stimulation transcranially and peripherally. An equal number of healthy children matched with regard to age, gender, and height served as the control group. RESULTS: The MEP latencies to the hands and legs elicited by stimulation at the cortex were prolonged significantly in the children treated for ALL compared with the control group, with the differences being 2.2 milliseconds [ms] (P < 0.001) from the cortex to the thenar on the right side and 2.0 ms (P < 0.001) on the left, and 1.4 ms (P = 0.004) from the cortex to the leg on the right side and 1.3 ms (P = 0.004) on the left. Correspondingly, the MEP latency from the fifth lumbar vertebrae (LV) level to the leg also was prolonged, by 1.0 ms (P = 0.005) on the right side and 0.8 ms (P = 0.005) on the left side. The calculated latency between the cortex and the LV level was not found to be significantly longer in those patients treated for ALL compared with the healthy controls. Neurologic signs, in the form of depressed deep tendon reflexes, were observed in 8% of the patients, whereas approximately 33% of the patients were found to have fine or gross motor difficulties and dysdiadochokinesia. CONCLUSIONS: Neurologic signs still persisted 5 years after therapy for ALL. Approximately 33% of the patients had fine or gross motor difficulties and dysdiadochokinesia, and demyelinative injuries to the peripheral nerve tracts were found proximally but not within the central nervous system. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10503
Authors: Michele Montgomery; Sujuan Huang; Cheryl L Cox; Wendy M Leisenring; Kevin C Oeffinger; Melissa M Hudson; Jill Ginsberg; Gregory T Armstrong; Leslie L Robison; Kirsten K Ness Journal: J Cancer Surviv Date: 2010-10-05 Impact factor: 4.442
Authors: Lang Li; Tammy Sajdyk; Ellen M L Smith; Chien Wei Chang; Claire Li; Richard H Ho; Raymond Hutchinson; Elizabeth Wells; Jodi L Skiles; Naomi Winick; Paul L Martin; Jamie L Renbarger Journal: Clin Pharmacol Ther Date: 2019-01-21 Impact factor: 6.875
Authors: Christian Savio; Alberto Garaventa; Marina Gremmo; Riccardo Camoriano; Luca Manfredini; Sara Fieramosca; Giorgio Dini; Maurizio Miano Journal: Support Care Cancer Date: 2006-08-29 Impact factor: 3.603
Authors: Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness Journal: Lancet Child Adolesc Health Date: 2018-09-01
Authors: Kirsten K Ness; Melissa M Hudson; Ching-Hon Pui; Daniel M Green; Kevin R Krull; Tseng T Huang; Leslie L Robison; E Brannon Morris Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: Marilyn J Hockenberry; Olga A Taylor; Patricia M Gundy; Adam K Ross; Alice Pasvogel; David Montgomery; Phillip Ribbeck; Kathy McCarthy; Ida Moore Journal: Biol Res Nurs Date: 2013-08-15 Impact factor: 2.522
Authors: Kirsten K Ness; Kendra E Jones; Webb A Smith; Sheri L Spunt; Carmen L Wilson; Gregory T Armstrong; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: Arch Phys Med Rehabil Date: 2013-03-26 Impact factor: 3.966
Authors: Kirsten K Ness; Sue C Kaste; Liang Zhu; Ching-Hon Pui; Sima Jeha; Paul C Nathan; Hiroto Inaba; Karen Wasilewski-Masker; Durga Shah; Robert J Wells; Robyn E Karlage; Leslie L Robison; Cheryl L Cox Journal: Leuk Lymphoma Date: 2014-08-20
Authors: Marilyn J Hockenberry; Kevin R Krull; Kathleen C Insel; Lynnette L Harris; Patricia M Gundy; Kristin B Adkins; Alice E Pasvogel; Olga A Taylor; Kari M Koerner; David W Montgomery; Adam K Ross; Adam Hill; Ida M Moore Journal: Oncol Nurs Forum Date: 2015-09 Impact factor: 2.172